Literature DB >> 27660342

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.

Paolo Gionchetti1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Axel Dignass1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Silvio Danese1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Fernando José Magro Dias1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Gerhard Rogler1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Péter Laszlo Lakatos1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Michel Adamina1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Sandro Ardizzone1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Christianne J Buskens1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Shaji Sebastian1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Silvio Laureti1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Gianluca M Sampietro1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Boris Vucelic1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, C Janneke van der Woude1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Manuel Barreiro-de Acosta1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Christian Maaser1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Francisco Portela1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Stephan R Vavricka1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19, Fernando Gomollón1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19.   

Abstract

This paper is the second in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease [CD] and concerns the surgical management of CD as well as special situations including management of perianal CD and extraintestinal manifestations. Diagnostic approaches and medical management of CD of this ECCO Consensus are covered in the first paper [Gomollon et al JCC 2016].
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; anti-TNFs; anti-integrins; biologics; budesonide; diagnosis; immunosuppressant; investigations; steroids; thiopurine; treatment

Mesh：

Year:  2016        PMID： 27660342     DOI： 10.1093/ecco-jcc/jjw169

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   10.020


  135 in total

1.  Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.

Authors:  Mingming Zhu; Xitao Xu; Qi Feng; Zhe Cui; Tianrong Wang; Yunqi Yan; Zhihua Ran
Journal:  Dig Dis Sci       Date:  2020-06-10       Impact factor: 3.199

Review 2.  The Biology of Anastomotic Healing-the Unknown Overwhelms the Known.

Authors:  Adam Lam; Brian Fleischer; John Alverdy
Journal:  J Gastrointest Surg       Date:  2020-06-10       Impact factor: 3.452

Review 3.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

4.  Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.

Authors:  Manca Ogrič; Polona Žigon; David Drobne; Borut Štabuc; Snezna Sodin-Semrl; Saša Čučnik; Sonja Praprotnik
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

5.  Risk factors associated with postoperative recurrence and repeat surgery in Japanese patients with Crohn's disease.

Authors:  Jun Kusaka; Hisashi Shiga; Masatake Kuroha; Tomoya Kimura; Yoichi Kakuta; Katsuya Endo; Yoshitaka Kinouchi; Tooru Shimosegawa
Journal:  Int J Colorectal Dis       Date:  2017-07-22       Impact factor: 2.571

6.  Diagnostic delay in patients with inflammatory bowel disease in Austria.

Authors:  Gottfried Novacek; Hans Peter Gröchenig; Thomas Haas; Heimo Wenzl; Pius Steiner; Robert Koch; Thomas Feichtenschlager; Gerald Eckhardt; Andreas Mayer; Andreas Kirchgatterer; Othmar Ludwiczek; Reingard Platzer; Pavol Papay; Johanna Gartner; Harry Fuchssteiner; Wolfgang Miehsler; Paul-Gerhard Peters; Gerhard Reicht; Harald Vogelsang; Clemens Dejaco; Thomas Waldhör
Journal:  Wien Klin Wochenschr       Date:  2019-02-04       Impact factor: 1.704

7.  [Inflammatory bowel diseases : Crohn's disease and ulcerative colitis].

Authors:  S Fischer; T Rath; M F Neurath
Journal:  Internist (Berl)       Date:  2018-07       Impact factor: 0.743

Review 8.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

9.  Pyloric and foveolar type metaplasia are important diagnostic features in Crohn's disease that are frequently missed in routine pathology.

Authors:  Soultana Meditskou; Alexandra Grekou; Alexandros Toskas; Theodora Papamitsou; Dimosthenis Miliaras
Journal:  Histol Histopathol       Date:  2019-09-20       Impact factor: 2.303

10.  When should we add a diverting loop ileostomy to laparoscopic ileocolic resection for primary Crohn's disease?

Authors:  Yong Sik Yoon; Luca Stocchi; Stefan Holubar; Alexandra Aiello; Sherief Shawki; Emre Gorgun; Scott R Steele; Conor P Delaney; Tracy Hull
Journal:  Surg Endosc       Date:  2020-05-28       Impact factor: 4.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.